M Vaughan

8.1k total citations · 1 hit paper
120 papers, 6.7k citations indexed

About

M Vaughan is a scholar working on Molecular Biology, Immunology and Cell Biology. According to data from OpenAlex, M Vaughan has authored 120 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 39 papers in Immunology and 26 papers in Cell Biology. Recurrent topics in M Vaughan's work include Toxin Mechanisms and Immunotoxins (35 papers), PARP inhibition in cancer therapy (18 papers) and Cellular transport and secretion (18 papers). M Vaughan is often cited by papers focused on Toxin Mechanisms and Immunotoxins (35 papers), PARP inhibition in cancer therapy (18 papers) and Cellular transport and secretion (18 papers). M Vaughan collaborates with scholars based in United States, Poland and Russia. M Vaughan's co-authors include Joel Moss, Vincent C. Manganiello, S C Tsai, Howard S. Kruth, Ronald Adamik, W. Gamble, Joel Avigan, Vincent Manganiello, Erik L. Hewlett and R L Kincaid and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

M Vaughan

119 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells.

1978 531 citations M Vaughan et al. profile →

Peers

Countries citing papers authored by M Vaughan

Since Specialization

Citations

This map shows the geographic impact of M Vaughan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Vaughan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Vaughan more than expected).

Fields of papers citing papers by M Vaughan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Vaughan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Vaughan. The network helps show where M Vaughan may publish in the future.

Co-authorship network of co-authors of M Vaughan

This figure shows the co-authorship network connecting the top 25 collaborators of M Vaughan. A scholar is included among the top collaborators of M Vaughan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Vaughan. M Vaughan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome 2025 ·Science Advances ·(unknown), Kenneth Ssebambulidde, (unknown), M Vaughan, Jintao Xu, Anutosh Ganguly, (unknown), Francisco Otaizo‐Carrasquero, Brian J. Song, Sijia Tao, Yoon‐Dong Park, (unknown), (unknown), Raymond F. Schinazi, Prashant Chittiboina, Bridgette Jeanne Billioux, Dima A. Hammoud, Michal A. Olszewski, Peter R. Williamson	1
2	Tocilizumab as a Potential Adjunctive Therapy to Corticosteroids in Cryptococcal Post-infectious Inflammatory Response Syndrome (PIIRS): a Report of Two Cases 2023 ·Journal of Clinical Immunology ·(unknown), (unknown), Kenneth Ssebambulidde, Yoon‐Dong Park, M Vaughan, (unknown), Dima A. Hammoud, Bridgette Jeanne Billioux, Peter R. Williamson	5
3	Engineering of glycosidases and glycosyltransferases 2006 ·Current Opinion in Chemical Biology ·Susan M. Hancock, M Vaughan, Stephen G. Withers	217
4	Functional expression and molecular pharmacology of hNaDC1 2003 ·The FASEB Journal ·(unknown), Diann M. McCoy, M Vaughan, Ana M. Pajor, (unknown), Sam M. Witherspoon	1
5	Enhancement of Cholera Toxin-Catalyzed ADP-Ribosylation by Guanine Nucleotide-Binding Proteins 1992 ·Current topics in microbiology and immunology ·(unknown), Joel Moss, M Vaughan	21
6	Human and Giardia ADP-ribosylation factors (ARFs) complement ARF function in Saccharomyces cerevisiae. 1992 ·Journal of Biological Chemistry ·Fang‐Jen S. Lee, Joel Moss, M Vaughan	33
7	Activation of cholera toxin and Escherichia coli heat‐labile enterotoxins by ADP‐ribosylation factors, a family of 20 kDa guanine nucleotide‐binding proteins 1991 ·Molecular Microbiology ·Joel Moss, M Vaughan	29
8	Molecular identification of ADP-ribosylation factor mRNAs and their expression in mammalian cells. 1991 ·Journal of Biological Chemistry ·M. Tsuchiya, S. Russ Price, S C Tsai, Joel Moss, M Vaughan	172
9	Structural and functional characterization of ADP-ribosylation factors, 20 kDa guanine nucleotide-binding proteins that activate cholera toxin. 1990 ·PubMed ·Joel Moss, M. Tsuchiya, Su-Chen Tsai, Ronald Adamik, David A. Bobak, S. Russ Price, Maria S. Nightingale, M Vaughan	0
10	Mechanism of cholera toxin activation by a guanine nucleotide-dependent 19 kDa protein 1990 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Mamoru Noda, Shang‐Yueh Tsai, Ronald Adamik, Joel Moss, M Vaughan	50
11	Guanine nucleotide-dependent ADP-ribosylation of soluble rho catalyzed by Clostridium botulinum C3 ADP-ribosyltransferase. Isolation and characterization of a newly recognized form of rhoA. 1990 ·Journal of Biological Chemistry ·Kim C. Williamson, Lewis J. Smith, Joel Moss, M Vaughan	14
12	Selective amplification of an mRNA and related pseudogene for a human ADP-ribosylation factor, a guanine nucleotide-dependent protein activator of cholera toxin. 1990 ·Proceedings of the National Academy of Sciences ·Lucia Monaco, (unknown), Ken B. Newman, S C Tsai, Joel Moss, M Vaughan	52
13	Molecular cloning, characterization, and expression of human ADP-ribosylation factors: two guanine nucleotide-dependent activators of cholera toxin. 1989 ·Proceedings of the National Academy of Sciences ·David A. Bobak, Maria S. Nightingale, James J. Murtagh, S. Russ Price, Joel Moss, M Vaughan	92
14	Structural and functional characterization of guanyl nucleotide-binding proteins using monoclonal antibodies to the alpha-subunit of transducin. 1986 ·Molecular Pharmacology ·Jane L. Halpern, S C Tsai, Ronald Adamik, Yasunori Kanaho, Eva Bekesi, Hsiang‐Fu Kung, Joel Moss, M Vaughan	9
15	Effect of Long and Short Photoperiod and/or Pinealectomy on Immunoreactive Somatostatin in the Syrian Hamster 1985 ·Hormone and Metabolic Research ·Susan M. Webb, Thomas H. Champney, M Vaughan, Ronald Reiter	3
16	Choleragen, adenylate cyclase, and ADP-ribosylation. 1984 ·PubMed ·M Vaughan	8
17	Choleragen-stimulated release of guanyl nucleotides from turkey erythrocyte membranes. 1982 ·Journal of Biological Chemistry ·Drusilla Burns, Joel Moss, M Vaughan	32
18	Products of reaction catalyzed by purified rat liver guanylate cyclase determined by 31p NMR spectroscopy. 1980 ·Proceedings of the National Academy of Sciences ·S C Tsai, H. Shindo, Vincent C. Manganiello, Ronald Adamik, M Vaughan	3
19	Activation and inhibition of fat cell adenylate cyclase by fluoride. 1976 ·Journal of Biological Chemistry ·Vincent C. Manganiello, M Vaughan	34
20	The appearance of lecithin-32P, synthesized from lysolecithin-32P, in phagosomes of polymorphonuclear leukocytes 1972 ·Journal of Clinical Investigation ·Peter Elsbach, Pierluigi Patriarca, P. Pettis, Thomas P. Stossel, Robert J. Mason, M Vaughan	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact